Publication
Birinapant enhances cisplatin sensitivity in epithelial ovarian cancer through modulation of apoptotic and survival signaling pathways.
Elham Shahnazi, Arman Rostamlou, Aras Gezer, Aysegul Uysal, Cumhur Gunduz
Cancer chemotherapy and pharmacologySep 8, 2026PMID 42709209doi:10.1007/s00280-026-04938-1 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 14, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260914-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Resistance to platinum-based chemotherapy in epithelial ovarian cancer is frequently driven by dysregulation of apoptotic pathways and overexpression of inhibitor of apoptosis proteins (IAPs). Smac mimetics, such as Birinapant, target IAPs and modulate TNF-α-associated signaling;…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Ovarian Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.